Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20Inflammatory Bowel DiseasePharmacology and Obesity TreatmentDiabetes Treatment and Management

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease—A Danish Nationwide Cohort Study

Nielsen, Jan, Friedman, Sonia, Nørgård, Bente Mertz, Knudsen, Torben, Kjeldsen, Jens, Wod, Mette·2025·Inflammatory Bowel Diseases
DOI 10.1093/ibd/izae276
Open this paper in CoChat — free account

Abstract

Background: There is a global increase in the prevalence of obesity, including among individuals with inflammatory bowel disease (IBD). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are potential anti-obesity medications due to their weight-lowering effects. However, concerns exist regarding ileus and intestinal obstruction as a severe side effect. Methods: This nationwide Danish cohort study evaluates the risk of ileus and intestinal obstruction in patients with IBD receiving GLP-1RAs. Patients with IBD and their exposure to GLP-1RAs were identified using Danish health registries. Cox regression analysis was used to estimate hazard ratios for the risk of ileus and intestinal obstruction adjusted for age at diagnosis of IBD, sex, type of IBD, prior ileus or intestinal obstruction, diabetes status, steroid use, and small bowel or colon surgery. Results: This study found that GLP-1RA exposure was not associated with an increased risk of ileus or intestinal obstruction in patients with IBD. Conclusion: This study suggests that GLP-1RAs do not increase the risk of ileus or intestinal obstruction in patients with IBD.

Overview

Integrity signals

Registry

Crossref · 10.1093/ibd/izae276

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 24

  1. Lynn, 2018, Su1855—prevalence of obesity and influence on phenotype within a population-based cohort of inflammatory bowel disease patients, Gastroenterology., 154, S-608, 10.1016/s0016-5085(18)32201-7 · DOI
  2. Lynn, 2018, Su1872—trends in the prevalence of overweight and obesity at the time of inflammatory bowel disease diagnosis: a population-based study, Gastroenterology., 154, S-614, 10.1016/s0016-5085(18)32218-2 · DOI
  3. Moran, 2013, The increasing weight of Crohn’s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis, Inflamm Bowel Dis., 19, 2949, 10.1097/MIB.0b013e31829936a4 · DOI
  4. Nic Suibhne, 2013, High prevalence of overweight and obesity in adults with Crohn’s disease: associations with disease and lifestyle factors, J Crohns Colitis., 7, e241, 10.1016/j.crohns.2012.09.009 · DOI
  5. Steed, 2009, A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland, Obes. Facts, 2, 370, 10.1159/000262276 · DOI
  6. Losurdo, 2020, Prevalence and associated factors of obesity in inflammatory bowel disease: a case-control study, World J Gastroenterol., 26, 7528, 10.3748/wjg.v26.i47.7528 · DOI
  7. Upadhyay, 2018, Pharmacotherapy of type 2 diabetes: an update, Metabolism, 78, 13, 10.1016/j.metabol.2017.08.010 · DOI
  8. Al-Dwairi, 2018, Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro, J Inflamm Res, 11, 95, 10.2147/JIR.S152835 · DOI
  9. Yazıcı, 2023, Clinical impact of glucagon-like peptide-1 receptor analogs on the complications of obesity, Obes Facts, 16, 149, 10.1159/000526808 · DOI
  10. Arvanitakis, 2023, GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use, Curr Obes Rep, 12, 61, 10.1007/s13679-023-00506-3 · DOI
  11. Pedersen, 2006, The Danish civil registration system. A cohort of eight million persons, Dan Med Bull., 53, 441
  12. Lynge, 2011, The Danish national patient register, Scand J Public Health., 39, 30, 10.1177/1403494811401482 · DOI · Paper page
  13. Schmidt, 2015, The Danish National Patient Registry: a review of content, data quality, and research potential, Clin Epidemiol, 7, 449, 10.2147/CLEP.S91125 · DOI
  14. Pottegård, 2017, Data resource profile: the Danish national prescription registry, Int J Epidemiol., 46, 798, 10.1093/ije/dyw213 · DOI
  15. Albaek Jacobsen, 2022, Validity of inflammatory bowel disease diagnoses in the Danish national patient registry: a population-based study from the North Denmark Region, Clin Epidemiol, 14, 1099, 10.2147/CLEP.S378003 · DOI
  16. Burisch, 2021, Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease, Therap Adv Gastroenterol., 14, 17562848211004841, 10.1177/17562848211004841 · DOI
  17. StataCorp, 2023, Stata Statistical Software: Release 18
  18. Marathe, 2011, Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function, Exp Diabetes Res., 2011, 279530, 10.1155/2011/279530 · DOI · Paper page
  19. Sodhi, 2023, Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss, JAMA., 330, 1795, 10.1001/jama.2023.19574 · DOI · Paper page
  20. Goldstone, 2019, Abdominal emergencies in inflammatory bowel disease, Surg Clin North Am., 99, 1141, 10.1016/j.suc.2019.08.007 · DOI
  21. Ueda, 2023, Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study, Clin Gastroenterol Hepatol., 22, 1226, 10.1016/j.cgh.2023.08.034 · DOI · Paper page
  22. Andersen, 1999, The Danish National Hospital register. a valuable source of data for modern health sciences, Dan Med Bull., 46, 263
  23. Fonager, 1996, Assessment of the diagnoses of Crohn’s disease and ulcerative colitis in a Danish hospital information system, Scand J Gastroenterol., 31, 154, 10.3109/00365529609031980 · DOI
  24. Ford, 2021, Crohn’s disease obstructions, Clin Colon Rectal Surg, 34, 227, 10.1055/s-0041-1729926 · DOI

Cited by

See all 20

Metadata

Authors
Nielsen, J., Friedman, S., Nørgård, B. M., Knudsen, T., Kjeldsen, J., & Wod, M.
Affiliations
  • University of Southern Denmark (DK)
  • Tufts University (US)
Corresponding author
Nielsen, Jan
ORCID
Venue
Inflammatory Bowel Diseases
Publisher
Oxford University Press (OUP)
Published
2024-11-27
Volume
31
Issue
7
Pages
1961-1965
ISSN
  • 1078-0998 (ISSN-L)
  • 1536-4844
DOI
10.1093/ibd/izae276
OpenAlex
W4404773596
Cited by
20
References
6
Citations by year
2026: 10 · 2025: 10
FWCI
5.29
Type
journal article
Language
en
Open access
closed
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • Inflammatory Bowel Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, ileus
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Denmark, Female, Humans, Intestinal Obstruction, Male, Middle Aged, Registries, Risk Factors, Inflammatory Bowel Diseases, Cohort Studies, Ileus, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.